| Somatotropin deficiency

Sogroya vs Humatrope

Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.

Deep comparison between: Sogroya vs Humatrope with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHumatrope has a higher rate of injection site reactions vs Sogroya based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Humatrope but not Sogroya, including UnitedHealthcare

Category

Sogroya

Humatrope

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGrowth hormone analog

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

Indications

Somatotropin deficiency
Noonan Syndrome

Somatotropin deficiency
Turner Syndrome
Short Stature Homeobox Deficiency
Growth retardation

Dosing

Somatotropin deficiency (pediatric) 0.16 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.

Noonan Syndrome, SGA, ISS 0.24 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.

Somatotropin deficiency (adult) Initiate 1.5 mg SC once weekly; titrate every 2-4 weeks by 0.5-1.5 mg to desired response; maximum 8 mg once weekly.

Somatotropin deficiency (pediatric) 0.18 mg/kg/week to 0.3 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Somatotropin deficiency (adult) Non-weight based: initiate at approximately 0.2 mg/day (range 0.15-0.3 mg/day), increase every 1-2 months by 0.1-0.2 mg/day per patient requirements; weight-based (not for obese patients): initiate at 0.006 mg/kg/day up to 0.0125 mg/kg/day; daily SC injection.

Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Short Stature Homeobox Deficiency 0.35 mg/kg/week (0.05 mg/kg/day) by SC injection.

Growth retardation Idiopathic Short Stature: up to 0.37 mg/kg/week; Small for Gestational Age: up to 0.47 mg/kg/week; divided into equal doses given 6 or 7 days per week by SC injection.

Contraindications

Acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Hypersensitivity to somapacitan-beco or any excipient
Pediatric patients with closed epiphyses
Active malignancy
Active proliferative or severe non-proliferative diabetic retinopathy
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient in HUMATROPE
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses in pediatric patients

Drug Interactions

254View drug interactions

267View drug interactions

Adverse Reactions

Most common (>=5%) Nasopharyngitis, respiratory tract infection, pyrexia, headache, pain in extremity, injection site reaction, diarrhea, vomiting, cough, ear infection

Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasm risk, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipohypertrophy/lipoatrophy, sudden death in Prader-Willi syndrome patients

Postmarketing Osteonecrosis in pediatric patients

Most common (>=5%) Edema, arthralgia, paresthesia, myalgia, pain, peripheral edema, headache, hypertension, rhinitis, back pain (adults); hypothyroidism, allergic reaction, arthralgia, bone disorder, injection site pain (pediatric GHD).

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipoatrophy.

Postmarketing Anaphylactic reactions, angioedema, increase in size or number of cutaneous nevi, gynecomastia, pancreatitis, new-onset type 2 diabetes mellitus, osteonecrosis, leukemia.

Pharmacology

Somapacitan-beco is a human growth hormone (hGH) analog that binds to a dimeric GH receptor in the cell membrane of target cells, triggering intracellular signal transduction and pharmacodynamic effects mediated both directly and through IGF-1 produced in the liver.

Somatropin is a recombinant human growth hormone that binds dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins (IGF-1, IGFBP-3, acid-labile subunit), with direct and IGF-1-mediated effects including stimulation of chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, and lipolysis, thereby promoting skeletal and linear growth in pediatric patients with GH deficiency.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Sogroya